tag kidney-research 
BioTech 365
JULY 20, 2021
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Ardelyx stock craters as FDA slaps biotech with dreaded ‘deficiencies’ tag on kidney drug.Ardelyx stock craters as FDA slaps biotech with dreaded ‘deficiencies’ tag on kidney drug … Continue reading →
Rethinking Clinical Trials
APRIL 27, 2023
The REB approved the MyTEMP request to use an altered patient consent process because the research was deemed of minimal risk to patients. MyTEMP worked with patients and caregivers to develop the trial, and Kidney Patient and Family Advisory Councils guided the choice of additional outcomes. degrees Celsius.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Rethinking Clinical Trials
FEBRUARY 16, 2023
There are also concerns that obtaining consent could alter the “real-world” medical care being studied, may introduce an alteration of routine care, may introduce bias or make research impossible to conduct. Think about methods of notification, from detailed study-specific information to a general statement that research is being conducted.
Rethinking Clinical Trials
AUGUST 22, 2022
Core Faculty, Program for Health Disparities Research. Trial participants were adults ages 30-85, who tested positive for SARS-CoV-2 within 3 days, with fewer than 7 days of symptoms, no known prior infection with SARS-CoV-2, no severe kidney, liver, or heart failure. Carolyn Bramante, MD, MPH. University of Minnesota Medical School.
Rethinking Clinical Trials
SEPTEMBER 22, 2022
Head of Cardiovascular Non-Invasive Imaging Research Laboratory. The national registries can be used to identify potential study participants who meet specific criteria and the e-BOKs system allows researchers to easily send invitations to potential participants, as well as follow up communications. Department of Biomedical Sciences.
XTalks
FEBRUARY 27, 2024
Rare Disease Day 2024, which falls on February 29 this year, is an opportunity to unite under a common cause: to bring attention to the challenges faced by those living with rare diseases and to push for advancements in research, treatment and policy. Sarepta hopes to clarify Elvidys’ effectiveness in older children in a confirmatory trial.
XTalks
OCTOBER 12, 2022
We [Philips Pharma Solutions, formerly BioTel Research] have successfully ran multi-site DCE-MRI trials,” said Edward Ashton, PhD, VP, Oncology Imaging, Philips Pharma Solutions. For ASL MR perfusion, water molecules in arterial blood from a feeder artery are magnetically tagged and tracked until they reach the region of interest.
Expert insights. Personalized for you.
40 
Let's personalize your content